The company’s loss from operations for the second quarter of 2011 was $6.28m, compared to $5.36m for the same period in 2010.
For the six months ended 30 June 2011, the company reported a net loss of $13.13m, compared to $7.24m for the same period in 2010.
Idera Pharma‘s loss from operations was $13.11m for the six months of 2011, compared to $7.1m for the same period in 2010.
Idera Pharma chairman and CEO Sudhir Agrawal said in their autoimmune disease program, they are reviewing the FDA comments on a Phase 2 protocol that they recently submitted to evaluate IMO-3100 in patients with psoriasis, and are assessing next steps to develop IMO-3100 in psoriasis.
"We also look forward to Merck KGaA completing the ongoing Phase 2 trial of IMO-2055 in combination with Erbitux for second-line treatment of head and neck cancer," Agrawal said.